Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

Delaying Menstruation: Evidence-Based Methods

Primary Method: Extended/Continuous Combined Hormonal Contraceptives

  • The American College of Obstetricians and Gynecologists recommends using combined hormonal contraceptives in an extended or continuous regimen to delay menstruation, by skipping the hormone-free interval and immediately starting the next cycle of active hormones, for women who want to delay their period 1, 2
  • Women already using combined oral contraceptives can skip the 7-day hormone-free interval and start a new pack of active pills to delay menstruation for as long as desired, without needing additional contraceptive protection 1
  • If combined hormonal contraceptives are started more than 5 days after menstrual bleeding began, backup contraception should be used for 7 days 3

Available Formulations

  • Combined hormonal contraceptives are available in various formulations, including oral contraceptive pills, transdermal patch, and vaginal ring, which release different amounts of estrogen and progestin daily 2, 3

Expected Bleeding Patterns and Management

  • Unscheduled spotting or bleeding is common during the first 3-6 months of extended or continuous use, but generally decreases with continued use, and is not harmful or a sign of method failure 1, 2
  • If breakthrough bleeding persists beyond 3-6 months, the patient should be evaluated for underlying problems such as pregnancy, medication interactions, or uterine pathology, and consider a 3-4 day hormone-free interval if no problem is found 1

Clinical Efficacy and Safety

  • Combined hormonal contraceptives delay menstruation by creating a thinner endometrial lining, inhibiting ovulation, and reducing prostaglandin production, which decreases uterine motility and cramping 2
  • Absolute contraindications to combined hormonal contraceptives include severe uncontrolled hypertension, ongoing hepatic dysfunction, and complicated valvular heart disease 2
  • The baseline risk of venous thromboembolism increases 3-4 fold with combined hormonal contraceptives, but remains lower than pregnancy-associated risk 2

Special Populations Who May Particularly Benefit

  • Women with menorrhagia, premenstrual symptoms, or other conditions that affect menstrual bleeding may particularly benefit from extended or continuous regimens of combined hormonal contraceptives 1, 2

Important Clinical Pearls

  • Lower-dose estrogen pills may show more follicular activity when missed, potentially increasing breakthrough bleeding risk, and monophasic formulations are preferred for extended use over multiphasic regimens 4, 5